JP2023504187A5 - - Google Patents

Info

Publication number
JP2023504187A5
JP2023504187A5 JP2022533071A JP2022533071A JP2023504187A5 JP 2023504187 A5 JP2023504187 A5 JP 2023504187A5 JP 2022533071 A JP2022533071 A JP 2022533071A JP 2022533071 A JP2022533071 A JP 2022533071A JP 2023504187 A5 JP2023504187 A5 JP 2023504187A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022533071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504187A (ja
JP7551750B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063390 external-priority patent/WO2021113697A1/en
Publication of JP2023504187A publication Critical patent/JP2023504187A/ja
Publication of JP2023504187A5 publication Critical patent/JP2023504187A5/ja
Priority to JP2024151893A priority Critical patent/JP2024170517A/ja
Application granted granted Critical
Publication of JP7551750B2 publication Critical patent/JP7551750B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022533071A 2019-12-05 2020-12-04 抗αvβ6抗体及び抗体薬物コンジュゲート Active JP7551750B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024151893A JP2024170517A (ja) 2019-12-05 2024-09-04 抗αvβ6抗体及び抗体薬物コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962943959P 2019-12-05 2019-12-05
US62/943,959 2019-12-05
US202063012584P 2020-04-20 2020-04-20
US63/012,584 2020-04-20
PCT/US2020/063390 WO2021113697A1 (en) 2019-12-05 2020-12-04 Anti-avb6 antibodies and antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024151893A Division JP2024170517A (ja) 2019-12-05 2024-09-04 抗αvβ6抗体及び抗体薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2023504187A JP2023504187A (ja) 2023-02-01
JP2023504187A5 true JP2023504187A5 (cg-RX-API-DMAC7.html) 2024-06-07
JP7551750B2 JP7551750B2 (ja) 2024-09-17

Family

ID=76222033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533071A Active JP7551750B2 (ja) 2019-12-05 2020-12-04 抗αvβ6抗体及び抗体薬物コンジュゲート
JP2024151893A Withdrawn JP2024170517A (ja) 2019-12-05 2024-09-04 抗αvβ6抗体及び抗体薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024151893A Withdrawn JP2024170517A (ja) 2019-12-05 2024-09-04 抗αvβ6抗体及び抗体薬物コンジュゲート

Country Status (12)

Country Link
US (3) US11827709B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069297A4 (cg-RX-API-DMAC7.html)
JP (2) JP7551750B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110231A (cg-RX-API-DMAC7.html)
CN (1) CN114828887B (cg-RX-API-DMAC7.html)
AU (1) AU2020397070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009570A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159414A1 (cg-RX-API-DMAC7.html)
IL (1) IL293195A (cg-RX-API-DMAC7.html)
MX (1) MX2022006132A (cg-RX-API-DMAC7.html)
TW (2) TWI884192B (cg-RX-API-DMAC7.html)
WO (1) WO2021113697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI884192B (zh) 2019-12-05 2025-05-21 美商西健公司 抗αVβ6抗體及抗體-藥物結合物
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
TW202417057A (zh) * 2022-10-26 2024-05-01 大陸商同潤生物醫藥(上海)有限公司 人源化的l1cam抗體藥物偶聯物
JP2025537099A (ja) 2022-11-03 2025-11-14 シージェン インコーポレイテッド 抗αVβ6抗体および抗体-薬物コンジュゲートならびにがんの治療におけるそれらの使用
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024263932A2 (en) 2023-06-23 2024-12-26 Mythic Therapeutics, Inc. Itgb6-binding proteins and uses thereof
WO2025064435A1 (en) * 2023-09-19 2025-03-27 Imaginab, Inc. Antigen binding constructs directed to integrin αvβ6
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026112478A1 (en) 2024-11-24 2026-05-28 Mythic Therapeutics, Inc. Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
NZ502546A (en) 1997-08-08 2002-02-01 Univ California Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
AU2002258808A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
WO2003087340A2 (en) 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US7241598B2 (en) 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
EA200700751A1 (ru) 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
EP1883424A2 (en) 2005-05-18 2008-02-06 Biogen Idec Inc. Methods for treating fibrotic conditions
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
KR20080039969A (ko) 2005-08-31 2008-05-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Gla 도메인을 결합하는 인간 fvii 단일클론의 항체및 이것의 사용
BRPI0714381A2 (pt) 2006-07-10 2013-03-05 Biogen Idec Inc composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
JP2010506944A (ja) 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαVβ6のアンタゴニストを用いる慢性喘息の処置および予防
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
AU2009203464A1 (en) 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
CN101959929B (zh) 2008-03-27 2013-05-01 泰尔茂株式会社 生物体吸收性材料及使用其的生物体内留置物
AU2009245724A1 (en) 2008-05-09 2009-11-12 Ablynx N.V. Amino acid sequences directed against integrins and uses thereof
BR112012003686B1 (pt) * 2009-08-19 2021-09-21 Merck Patent Gmbh Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
WO2011046309A2 (en) 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
MX361929B (es) * 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
CN105017420B (zh) * 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
US20150086570A1 (en) 2012-03-29 2015-03-26 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications
US10035859B2 (en) * 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
BR112016002753A2 (pt) * 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
CN106232625B (zh) * 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
KR102321861B1 (ko) * 2017-03-10 2021-11-05 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도
EP3630844A4 (en) * 2017-05-30 2021-03-03 Chong Kun Dang Pharmaceutical Corp. NOVEL ANTI-C-MET ANTIBODY AND USE OF IT
US20210363259A1 (en) * 2017-08-22 2021-11-25 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
GB201814562D0 (en) * 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
TWI884192B (zh) 2019-12-05 2025-05-21 美商西健公司 抗αVβ6抗體及抗體-藥物結合物
EP4518905A1 (en) * 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates

Similar Documents

Publication Publication Date Title
US11897961B2 (en) Anti-CD123 antibodies and conjugates and derivatives thereof
US20240226318A1 (en) Antibody drug conjugate targeting nectin 4 and preparation method therefor and use thereof
US11819553B2 (en) Glypican 3 antibodies and conjugates thereof
US9822183B2 (en) CA6 antigen-specific cytotoxic conjugate and methods of using the same
CN106729743B (zh) 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
WO2023036137A1 (en) Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies
JP2021513844A5 (cg-RX-API-DMAC7.html)
JP2015523380A5 (cg-RX-API-DMAC7.html)
US20050123549A1 (en) CA6 antigen-specific cytotoxic conjugate and methods of using the same
JP2015523961A5 (cg-RX-API-DMAC7.html)
JP2017522861A5 (cg-RX-API-DMAC7.html)
JP2022530524A5 (cg-RX-API-DMAC7.html)
JP2017534253A5 (cg-RX-API-DMAC7.html)
JP7510518B2 (ja) 抗c-Met抗体薬物複合体及びその応用
JP2012522513A5 (cg-RX-API-DMAC7.html)
JP2014509835A5 (cg-RX-API-DMAC7.html)
RU2011144141A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2016523810A5 (cg-RX-API-DMAC7.html)
JP2015533781A5 (cg-RX-API-DMAC7.html)
AU2005335743A1 (en) A CA6 antigen-specific cytotoxic conjugate and methods of using the same
WO2023001300A1 (zh) 艾日布林衍生物的药物偶联物
JP2015529656A5 (cg-RX-API-DMAC7.html)
JP2026512687A (ja) ヒト化l1cam抗体-薬物複合体
RU2859403C2 (ru) Конъюгат антитела с лекарственным средством, нацеливающийся на нектин-4, и способ его получения и его применение
RU2025111318A (ru) АНТИ-αvβ6 АНТИТЕЛА И КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА